{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:29:34Z","timestamp":1768012174225,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nephropathic cystinosis is a rare lysosomal storage disorder in which accumulation of cystine and formation of crystals particularly impair kidney function and gradually lead to multi-organ dysfunction. Lifelong therapy with the aminothiol cysteamine can delay the development of kidney failure and the need for transplant. The purpose of our long-term study was to explore the effects of transitioning from immediate release (IR) to extended release (ER) formulation in Norwegian patients in routine clinical care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analysed data on efficacy and safety in 10 paediatric and adult patients. Data were obtained from up to 6\u00a0years before and 6\u00a0years after transitioning from IR- to ER-cysteamine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean white blood cell (WBC) cystine levels remained comparable between the different treatment periods (1.19 versus 1.38\u00a0nmol hemicystine\/mg protein) although most patients under ER-cysteamine underwent dose reductions. For the non-transplanted patients, the mean estimated glomerular filtration rate (eGFR) change\/year was more pronounced during ER-treatment (\u2212\u20093.39 versus\u2009\u2212\u20096.80\u00a0ml\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>\/year) possibly influenced by individual events, such as tubulointerstitial nephritis and colitis. Growth measured by Z-height score tended to develop positively. Four of seven patients reported improvement of halitosis, one reported unchanged and two reported worsened symptoms. Most adverse drug reactions (ADRs) were of mild severity. One patient developed two serious ADRs and switched back to IR-formulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results from this long-term retrospective study indicate that switching from IR- to ER-cysteamine was feasible and well tolerated under routine clinical practice. ER-cysteamine allowed satisfactory disease control over the long period considered.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00467-023-06005-w","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:02:18Z","timestamp":1684846938000},"page":"3671-3679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effects of transitioning from immediate release to extended release cysteamine therapy in Norwegian patients with nephropathic cystinosis: a retrospective study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-0098","authenticated-orcid":false,"given":"Anna","family":"Bjerre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja Amdal","family":"Aase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Siva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Gudmundsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brita","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Woldseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Brackman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"6005_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ki.2011.277","volume":"81","author":"A Brodin-Sartorius","year":"2012","unstructured":"Brodin-Sartorius A, T\u00eate MJ, Niaudet P, Antignac C, Guest G, Ottolenghi C, Charbit M, Moyse D, Legendre C, Lesavre P, Cochat P, Servais A (2012) Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int 81:179\u2013189","journal-title":"Kidney Int"},{"key":"6005_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7326\/0003-4819-147-4-200708210-00006","volume":"147","author":"WA Gahl","year":"2007","unstructured":"Gahl WA, Balog JZ, Kleta R (2007) Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy. Ann Intern Med 147:242\u2013250","journal-title":"Ann Intern Med"},{"key":"6005_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00467-012-2242-5","volume":"28","author":"G Nesterova","year":"2013","unstructured":"Nesterova G, Gahl WA (2013) Cystinosis: the evolution of a treatable disease. Pediatr Nephrol 28:51\u201359","journal-title":"Pediatr Nephrol"},{"key":"6005_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1126\/science.7112129","volume":"217","author":"WA Gahl","year":"1982","unstructured":"Gahl WA, Bashan N, Tietze F, Bernardini I, Schulman JD (1982) Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science 217:1263\u20131265","journal-title":"Science"},{"key":"6005_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMra020552","volume":"347","author":"WA Gahl","year":"2002","unstructured":"Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. N Engl J Med 347:111\u2013121","journal-title":"N Engl J Med"},{"key":"6005_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00467-016-3438-x","volume":"32","author":"T Ahlenstiel-Grunow","year":"2017","unstructured":"Ahlenstiel-Grunow T, Kanzelmeyer NK, Froede K, Kreuzer M, Drube J, Lerch C, Pape L (2017) Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study. Pediatr Nephrol 32:91\u201397","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 4","key":"6005_CR7","doi-asserted-by":"publisher","first-page":"iv87","DOI":"10.1093\/ndt\/gfu090","volume":"29","author":"F Emma","year":"2014","unstructured":"Emma F, Nesterova G, Langman C, Labb\u00e9 A, Cherqui S, Goodyer P, Janssen MC, Greco M, Topaloglu R, Elenberg E, Dohil R, Trauner D, Antignac C, Cochat P, Kaskel F, Servais A, W\u00fchl E, Niaudet P, Van\u2019t Hoff W, Gahl W, Levtchenko E (2014) Nephropathic cystinosis: an international consensus document. Nephrol Dial Transplant 29(Suppl 4):iv87-94","journal-title":"Nephrol Dial Transplant"},{"key":"6005_CR8","unstructured":"Summary of Product Characteristics (SmPC): Cystagon RRD. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cystagon-epar-product-information_en.pdf. Accessed Nov 2021"},{"key":"6005_CR9","unstructured":"Summary of Product Characteristics (SmPC): Procysbi CFSpA. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/procysbi-epar-product-information_en.pdf. Accessed Aug 2021"},{"key":"6005_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-016-0426-y","volume":"11","author":"MA Elmonem","year":"2016","unstructured":"Elmonem MA, Veys KR, Soliman NA, van Dyck M, van den Heuvel LP, Levtchenko E (2016) Cystinosis: a review. Orphanet J Rare Dis 11:47","journal-title":"Orphanet J Rare Dis"},{"key":"6005_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ndt\/gfu329","volume":"30","author":"G Ariceta","year":"2015","unstructured":"Ariceta G, Lara E, Camacho JA, Oppenheimer F, Vara J, Santos F, Mu\u00f1oz MA, Cantarell C, Gil Calvo M, Romero R, Valenciano B, Garc\u00eda-Nieto V, Sanahuja MJ, Crespo J, Justa ML, Urisarri A, Bedoya R, Bueno A, Daza A, Bravo J, Llamas F, Jim\u00e9nez Del Cerro LA (2015) Cysteamine (Cystagon\u00ae) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adults. Nephrol Dial Transplant 30:475\u2013480","journal-title":"Nephrol Dial Transplant"},{"key":"6005_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00467-005-2052-0","volume":"21","author":"EN Levtchenko","year":"2006","unstructured":"Levtchenko EN, van Dael CM, de Graaf-Hess AC, Wilmer MJ, van den Heuvel LP, Monnens LA, Blom HJ (2006) Strict cysteamine dose regimen is required to prevent nocturnal cystine accumulation in cystinosis. Pediatr Nephrol 21:110\u2013113","journal-title":"Pediatr Nephrol"},{"key":"6005_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ymgme.2012.06.017","volume":"107","author":"M Besouw","year":"2012","unstructured":"Besouw M, Tangerman A, Cornelissen E, Rioux P, Levtchenko E (2012) Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate. Mol Genet Metab 107:234\u2013236","journal-title":"Mol Genet Metab"},{"key":"6005_CR14","first-page":"615","volume":"269","author":"D Cairns","year":"2002","unstructured":"Cairns D, Anderson RJ, Coulthard MB, Terry J (2002) Cystinosis and its treatment. Pharm J 269:615\u2013616","journal-title":"Pharm J"},{"key":"6005_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jpeds.2014.05.013","volume":"165","author":"CB Langman","year":"2014","unstructured":"Langman CB, Greenbaum LA, Grimm P, Sarwal M, Niaudet P, Deschenes G, Cornelissen EA, Morin D, Cochat P, Elenberg E, Hanna C, Gaillard S, Bagger MJ, Rioux P (2014) Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate. J Pediatr 165:528-533.e521","journal-title":"J Pediatr"},{"key":"6005_CR16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2215\/CJN.12321211","volume":"7","author":"CB Langman","year":"2012","unstructured":"Langman CB, Greenbaum LA, Sarwal M, Grimm P, Niaudet P, Desch\u00eanes G, Cornelissen E, Morin D, Cochat P, Matossian D, Gaillard S, Bagger MJ, Rioux P (2012) A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol 7:1112\u20131120","journal-title":"Clin J Am Soc Nephrol"},{"key":"6005_CR17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.kint.2020.10.017","volume":"99","author":"J Bj\u00f6rk","year":"2021","unstructured":"Bj\u00f6rk J, Nyman U, Larsson A, Delanaye P, Pottel H (2021) Estimation of the glomerular filtration rate in children and young adults by means of the CKD-EPI equation with age-adjusted creatinine values. Kidney Int 99:940\u2013947","journal-title":"Kidney Int"},{"key":"6005_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jpeds.2009.11.059","volume":"156","author":"R Dohil","year":"2010","unstructured":"Dohil R, Gangoiti JA, Cabrera BL, Fidler M, Schneider JA, Barshop BA (2010) Long-term treatment of cystinosis in children with twice-daily cysteamine. J Pediatr 156:823\u2013827","journal-title":"J Pediatr"},{"key":"6005_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13023-021-01991-2","volume":"16","author":"C van Stein","year":"2021","unstructured":"van Stein C, Klank S, Gr\u00fcneberg M, Ottolenghi C, Grebe J, Reunert J, Harms E, Marquardt T (2021) A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis. Orphanet J Rare Dis 16:387","journal-title":"Orphanet J Rare Dis"},{"key":"6005_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJM199304223281604","volume":"328","author":"TC Markello","year":"1993","unstructured":"Markello TC, Bernardini IM, Gahl WA (1993) Improved renal function in children with cystinosis treated with cysteamine. N Engl J Med 328:1157\u20131162","journal-title":"N Engl J Med"},{"key":"6005_CR21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00467-017-3618-3","volume":"32","author":"S B\u00e4umner","year":"2017","unstructured":"B\u00e4umner S, Weber LT (2017) Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects. Pediatr Nephrol 32:1281\u20131282","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-06005-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:07:59Z","timestamp":1695294479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-06005-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6005"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-06005-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective nature of the study, the Norwegian Ethics Committees assessed the project to be a quality assurance project outside the Health Research Act, and therefore, there was no need to approve the study. The sponsor has also been in contact with the Norwegian Directorate of Health. No approval from them was needed since the patients voluntarily signed the informed consent. This was in accordance with the General Data Protection Regulation (GDPR) art. 7. Before study initiation, the local Privacy Officer at each hospital evaluated the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Chiesi Global Rare Diseases has reimbursed all participating sites, per the number of hours preparing and performing the study. Oslo University Hospital has received speakers\u2019 honoraria and travel grants for Anna Bjerre from Chiesi Global Rare Diseases Nordics. The departments of AB and BW have received consultation fees from Chiesi Global Rare Diseases. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}